TYRO3 inhibits anti-PD-1/PD-L1-induced ferrogenesis in tumor cells by suppressing the AKT/NRF2 axis and amplifies a favorable tumor microenvironment by reducing the ratio of M1/M2 macrophages, thus contributing to the efficacy of anti-PD-1/PD-L1 therapy (88). The gene discussed is AKT1; the disease is neoplasm.